Medimmune Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Medimmune ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Medimmune Ltd Today - Breaking & Trending Today
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy. DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in MPM with the combination of chemotherapy and durvalumab, and warrant confirmation in a randomized phase 3 trial. ....
E-Mail IMAGE: Patrick Forde, MD, is the lead US investigator for the newly opened DREAM3R clinical trial, which is evaluating chemo-immunotherapy in patients with malignant pleural mesothelioma. view more Credit: Johns Hopkins University The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials, PrE0505 and DREAM. These trials evaluated durvalumab immunotherapy during and after standard chemotherapy. DREAM3R will determine if concurrent chemo-immunotherapy can improve outcomes in malignant pleural mesothelioma, especially for the majority of patients with the epithelioid subtype, said lead US investigator Patrick Forde, MD, of Johns Hopkins University. Both the DREAM and PrE0505 phase 2 trials showed remarkable results in ....
Search jobs NanoSyrinx strengthens board with appointment of Dr Jane Dancer as Non-Executive Director Coventry, UK, 10th December 2020 / Sciad Newswire / NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director. NanoSyrinx is an early-stage biotechnology company using synthetic biology approaches to develop a completely novel platform for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells. Dr Dancer has over 30 years’ experience in business development across biotech, pharma and agrochemicals and her experience will help to drive NanoSyrinx’s ongoing fundraising activities and ambitious growth plans. Dr Dancer is a highly experienced business leader with previous roles including Chief Business Officer at F-star, Vice President of Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane ....